NIH frames perimenopause as key to women’s midlife health

Established in 1990, the NIH Office of Research on Women’s Health is treating perimenopause as a normal life stage with outsized importance for women’s midlife health. The evidence still has too many gaps to ignore. Symptoms are uneven, consequences can spill into sleep and work, and questions around brain and heart health stretch well beyond the last menstrual period.

Menopause is normal, but the science is not finished

The NIH Office of Research on Women’s Health defines menopause as the permanent end of menstrual cycling and perimenopause as the transitional period leading up to it. That approach is broader than the old symptom-only view: it treats menopause as part of a life-course approach to women’s health, not as a single clinical event. ORWH identifies gaps, creates discussion, and stimulates and supports research before, during and after the menopausal transition.

It offers a plain-language explanation for patients and clinicians and signals federal priorities: menopause belongs on the same research map as cardiovascular health, cognition, bone health and social determinants of health.

What perimenopause looks like in real life

Most women experience menopause between ages 45 and 55, but the transition into it is where many of the day-to-day disruptions begin. Common symptoms include hot flashes, vaginal dryness and mood changes, and symptom severity varies widely. Some people move through the transition with mild changes; others have symptoms that are persistent enough to affect sleep, concentration, energy and quality of life.

That variability is one reason the field still needs better patient-centered tools. A one-size-fits-all approach misses the difference between occasional discomfort and a pattern that is interrupting daily functioning. It also misses the fact that perimenopause often arrives while women are still working full-time, caring for families and managing the physical changes of midlife all at once.

Sleep is one of the clearest pressure points

Among the symptoms under scrutiny, sleep stands out because the data already show a measurable difference by menopausal stage. In CDC and National Center for Health Statistics data on women aged 40 to 59, 56.0% of perimenopausal women slept less than 7 hours in a 24-hour period, compared with 40.5% of postmenopausal women and 32.5% of premenopausal women. That does not prove causation, but it shows that the transition is not just about hot flashes that happen in isolation from the rest of life.

Broken sleep affects mood, exercise capacity, appetite regulation and work performance, and it can make the transition feel more destabilizing than the label suggests. The research priority now is not simply whether sleep gets shorter, but how to identify which women are most affected, what interventions help most, and how to separate hormone-related sleep disruption from the other pressures of midlife.

The open questions are about more than symptoms

The NIH and the National Institute on Aging have linked menopause-related midlife changes to later-life brain and heart health questions. The unanswered issue is not whether menopause is real, but how the transition interacts with long-term risk for cognition, cardiovascular disease and other age-related outcomes.

The long-running Study of Women’s Health Across the Nation is central to that effort. SWAN began in the late 1990s and has followed more than 3,000 multiethnic women at seven centers across the United States, tracking physical, biological, psychological and social changes before, during and after menopause. Its scope reflects what the field now understands: this transition cannot be reduced to estrogen alone, because health outcomes are shaped by biology, race, stress, work, sleep and social context as well as hormones.

What the evidence supports now, and what is still being refined

The Menopause Society released an updated 2023 nonhormone therapy position statement to provide scientifically based recommendations for bothersome symptoms such as hot flashes. It is aimed at people who cannot or do not want to use hormone therapy and reflects a broader effort to build a more complete toolbox for symptom management. Evidence-based nonhormone options matter because many women need help before, after or instead of hormone treatment.

The caution is that the marketplace around menopause often runs ahead of the evidence. Supported approaches need to be separated from what is merely well marketed. If an approach promises to solve sleep, mood, cognition and body composition all at once, the burden of proof should be high. The strongest case for any intervention is still one that is tied to a defined symptom, a documented need and a realistic expectation of benefit.

When the transition deserves medical attention

Perimenopause does not automatically mean something is wrong, but it does deserve attention when symptoms are becoming disruptive. Sleep that repeatedly drops below a healthy baseline, mood changes that feel persistent, vaginal dryness that affects comfort or hot flashes that interfere with daily life are all worth raising with a GP or menopause clinician.